News – Featured

Tropical Storm Francine is active in the Gulf of Mexico and is expected to develop into a hurricane. These weather conditions may impact areas in the United States, including Alabama, Arkansas, Louisiana, Mississippi, Tennessee, and Texas. We continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the impacted areas should expect to be contacted directly if any routes are modified or canceled.

By Mayo Clinic Laboratories • September 10, 2024

William Morice II, M.D., Ph.D., recently joined the Advisory Board for a webinar discussion on 2024 lab market trends. Dr. Morice covered the current lab market outlook, the priority trends, and opportunities for future growth.

By Luci Gens • August 27, 2024

As Hurricane Debby moves through the Southeast United States (Florida, Georgia, South Carolina, North Carolina, and Virginia), we continue to monitor and track the situation with our logistics partners to minimize challenges. Clients in the impacted areas should expect to be contacted directly if any routes are modified or canceled.

By Mayo Clinic Laboratories • August 5, 2024

Mayo Clinic Laboratories specimen pickup and delivery schedules will be altered due to the upcoming holiday. To ensure specimen stability and prevent delays, follow these guidelines.

By Mayo Clinic Laboratories • August 5, 2024

Mayo Clinic Laboratories is aware of the Microsoft outage that is impacting domestic and international shipments. We are actively monitoring the situation and making carrier adjustments as needed

By Mayo Clinic Laboratories • July 19, 2024

Presented by Mayo Clinic Laboratories, "Leveraging the Laboratory: Seize Tomorrow" is an essential conference for health system executives, industry experts, and hands-on managers looking to advance their laboratory outreach programs.

By Carly Mouzes • June 18, 2024

Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered due to the upcoming July 4th holiday. To ensure specimen stability and prevent delays, follow the guidelines outlined below for domestic clients and international clients.

By Mayo Clinic Laboratories • June 18, 2024

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, authored a Becker’s Healthcare article on how hospital laboratories can navigate times of change and uncertainty with the steadfast support of a business partner like Mayo Clinic Laboratories.

By Luci Gens • May 22, 2024

In a landmark discovery published in Clinical Chemistry, authenticated locks of hair from the composer Ludwig van Beethoven have revealed high lead concentrations after being analyzed at Mayo Clinic. Paul Jannetto, Ph.D., director of the Metals Laboratory at Mayo Clinic, along with his laboratory staff, completed testing on two independent and authenticated locks of Beethoven’s hair which confirmed the presence of high lead concentrations and could explain the cause for many of Beethoven’s ailments.

By Luci Gens • May 9, 2024

As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.

By Mayo Clinic Laboratories • May 1, 2024

Mary Jo Williamson, chief administrative officer of Mayo Clinic Laboratories, joins the “Fierce Healthcare” podcast to discuss how organizations can cultivate resiliency and agility amidst a changing healthcare landscape.

By Luci Gens • April 24, 2024

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, is a contributing author on Nasdaq.com. In his latest article, he discusses sustainability in laboratories and the interconnectivity of environmental health and public health.

By Luci Gens • April 22, 2024

Mayo Clinic Laboratories has marked a significant advancement in the fight against Alzheimer's disease with the introduction of an innovative diagnostic test. This noninvasive blood test accurately detects the p-Tau217 biomarker, indicative of amyloid beta accumulation in the brain. This test is set to transform the approach to Alzheimer's disease management, offering a convenient and less invasive alternative to traditional diagnostic methods.

By Luci Gens • April 17, 2024